Geneva, Switzerland - 13 Dec - 16 Dec 2018 The ESMO Immuno-Oncology Congress, page-22

LoL fp, at 2.3c last week you probably bought mine.

That’s nothing to what GSK spent on Tesaro last week, $5.1b deal!

https://www.fiercepharma.com/pharma/glaxosmithkline-looking-to-pump-up-new-favorite-oncology-buys-tesaro-for-5-1b

I was thinking IMU would turn out to be the next CSL, but after Paul’s interview, I felt slightly disappointed that we’re only after a VLA style buy out. On the other hand, I can see how this can possibly play out:

Back in April, after getting positive initial trial results, Axel recommended the board to buy out other B-cell vaccine trials (OSU/Mayo) to ensure IMU monopolise B-cell vaccines with the view of one day being bought by GSK.

We are a research arm of GSK but At the moment it’s cheaper & less risk for them to let Imugene stays as an independent company to do the trials.

If the vaccine works & in combo with the anti PD1 etc, can be produced at cheaper cost than the competitors & we are the only one in the game, you’d think multi billion $ reward is waiting if the trials are successful.

Anyway, just a wishful thinking..